BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 27001435)

  • 41. Challenging lesions in the differential diagnosis of endocrine tumors: parathyroid carcinoma.
    Delellis RA
    Endocr Pathol; 2008; 19(4):221-5. PubMed ID: 19058032
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism.
    van der Tuin K; Tops CMJ; Adank MA; Cobben JM; Hamdy NAT; Jongmans MC; Menko FH; van Nesselrooij BPM; Netea-Maier RT; Oosterwijk JC; Valk GD; Wolffenbuttel BHR; Hes FJ; Morreau H
    J Clin Endocrinol Metab; 2017 Dec; 102(12):4534-4540. PubMed ID: 29040582
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A germline mutation of HRPT2/CDC73 (70 G>T) in an adolescent female with parathyroid carcinoma: first case report and a review of the literature.
    Serrano-Gonzalez M; Shay S; Austin J; Maceri DR; Pitukcheewanont P
    J Pediatr Endocrinol Metab; 2016 Sep; 29(9):1005-12. PubMed ID: 27544721
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.
    Howell VM; Gill A; Clarkson A; Nelson AE; Dunne R; Delbridge LW; Robinson BG; Teh BT; Gimm O; Marsh DJ
    J Clin Endocrinol Metab; 2009 Feb; 94(2):434-41. PubMed ID: 19017757
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetic defects associated with familial and sporadic hyperparathyroidism.
    Hendy GN; Cole DE
    Front Horm Res; 2013; 41():149-65. PubMed ID: 23652676
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epigenetic Alterations in Parathyroid Cancers.
    Verdelli C; Corbetta S
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28157158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular pathogenesis of primary hyperparathyroidism.
    Cetani F; Pardi E; Borsari S; Marcocci C
    J Endocrinol Invest; 2011 Jul; 34(7 Suppl):35-9. PubMed ID: 21985978
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association Between Parafibromin Expression and Presence of Brown Tumors and Jaw Tumors in Patients with Primary Hyperparathyroidism: Series of Cases with Review of the Literature.
    Popow M; Kaszczewska M; Góralska M; Kaszczewski P; Skwarek-Szewczyk A; Chudziński W; Jażdżewski K; Kolanowska M; Bogdańska M; Starzyńska-Kubicka A; Gałązka Z
    Am J Case Rep; 2022 Oct; 23():e936135. PubMed ID: 36271606
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early-onset, severe, and recurrent primary hyperparathyroidism associated with a novel CDC73 mutation.
    Shibata Y; Yamazaki M; Takei M; Uchino S; Sakurai A; Komatsu M
    Endocr J; 2015; 62(7):627-32. PubMed ID: 25959515
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HIGH RISK OF PARATHYROID CARCINOMA AND GENETIC SCREENING IN THE FIRST DIAGNOSED ROMANIAN FAMILY WITH HYPERPARATHYROIDISM-JAW TUMOR SYNDROME AND A GERMLINE MUTATION OF THE CDC73 GENE.
    Grigorie D; Sucaliuc A; Ciuffi S; Franceschelli F; Marini F; Ioachim D; Terzea D; Brandi MLL
    Acta Endocrinol (Buchar); 2019; 15(3):398-403. PubMed ID: 32010362
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma.
    Kim HK; Oh YL; Kim SH; Lee DY; Kang HC; Lee JI; Jang HW; Hur KY; Kim JH; Min YK; Chung JH; Kim SW
    Head Neck; 2012 Feb; 34(2):201-6. PubMed ID: 21717519
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma.
    Tan MH; Morrison C; Wang P; Yang X; Haven CJ; Zhang C; Zhao P; Tretiakova MS; Korpi-Hyovalti E; Burgess JR; Soo KC; Cheah WK; Cao B; Resau J; Morreau H; Teh BT
    Clin Cancer Res; 2004 Oct; 10(19):6629-37. PubMed ID: 15475453
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Novel Mutation in a Patient with Hyperparathyroidism-Jaw Tumour Syndrome.
    Bellido V; Larrañaga I; Guimón M; Martinez-Conde R; Eguia A; Perez de Nanclares G; Castaño L; Gaztambide S
    Endocr Pathol; 2016 Jun; 27(2):142-6. PubMed ID: 26995009
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort.
    Guarnieri V; Battista C; Muscarella LA; Bisceglia M; de Martino D; Baorda F; Maiello E; D'Agruma L; Chiodini I; Clemente C; Minisola S; Romagnoli E; Corbetta S; Viti R; Eller-Vainicher C; Spada A; Iacobellis M; Malavolta N; Carella M; Canaff L; Hendy GN; Cole DE; Scillitani A
    Cell Oncol (Dordr); 2012 Dec; 35(6):411-22. PubMed ID: 22987117
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Parafibromin Abnormalities in Ossifying Fibroma.
    Costa-Guda J; Pandya C; Strahl M; Taik P; Sebra R; Chen R; Uzilov AV; Arnold A
    J Endocr Soc; 2021 Jul; 5(7):bvab087. PubMed ID: 34159287
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism.
    Masi G; Barzon L; Iacobone M; Viel G; Porzionato A; Macchi V; De Caro R; Favia G; Palù G
    Endocr Relat Cancer; 2008 Dec; 15(4):1115-26. PubMed ID: 18755853
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue.
    Corbetta S; Vaira V; Guarnieri V; Scillitani A; Eller-Vainicher C; Ferrero S; Vicentini L; Chiodini I; Bisceglia M; Beck-Peccoz P; Bosari S; Spada A
    Endocr Relat Cancer; 2010 Mar; 17(1):135-46. PubMed ID: 19926710
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours.
    Juhlin CC; Haglund F; Obara T; Arnold A; Larsson C; Höög A
    Virchows Arch; 2011 Jul; 459(1):47-53. PubMed ID: 21221636
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pediatric Parathyroid Carcinoma: A Case Report and Review of the Literature.
    Dutta A; Pal R; Jain N; Dutta P; Rai A; Bhansali A; Behera A; Saikia UN; Vishwajeet V; Collier D; Boon H; Korbonits M; Bhadada SK
    J Endocr Soc; 2019 Dec; 3(12):2224-2235. PubMed ID: 31723720
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Familial isolated primary hyperparathyroidism/hyperparathyroidism-jaw tumour syndrome caused by germline gross deletion or point mutations of CDC73 gene in Chinese.
    Kong J; Wang O; Nie M; Shi J; Hu Y; Jiang Y; Li M; Xia W; Meng X; Xing X
    Clin Endocrinol (Oxf); 2014 Aug; 81(2):222-30. PubMed ID: 24716902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.